Quick Answer
IRONWOOD PHARMACEUTICALS INC reported Operating Income Loss of $98.50 million for the year ending 2025.
- IRONWOOD PHARMACEUTICALS INC showed an increase of +5.8% in Operating Income Loss from 2024 to 2025.
- This data is from IRONWOOD PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), IRONWOOD PHARMACEUTICALS INC's Operating Income Loss has grown by 262.0%.
- Historical annual values: Fiscal year 2025: $98.50 million | Fiscal year 2024: $93.12 million | Fiscal year 2023: -$945.43 million | Fiscal year 2022: $250.34 million | Fiscal year 2021: $232.26 million | Fiscal year 2020: $142.94 million | Fiscal year 2019: $120.12 million | Fiscal year 2018: -$150.67 million | Fiscal year 2017: -$15.36 million | Fiscal year 2016: -$51.87 million | Fiscal year 2015: -$102.09 million | Fiscal year 2014: -$169.37 million | Fiscal year 2013: -$252.00 million | Fiscal year 2012: -$72.76 million | Fiscal year 2011: -$66.14 million | Fiscal year 2010: -$60.77 million | Fiscal year 2009: -$60.82 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: